MRKMerck Sharp & Dohme LLCSigning up patients
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Non-small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Mar 30, 2025
- Main results expected
- Mar 12, 2032
- Fully finished
- Mar 12, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: Up to ~ 5 years
Number of Participants with Adverse Events (AEs)
Measured over: Up to ~ 5 years
Number of Participants Discontinuing Study Drug Due to AEs
Measured over: Up to ~ 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06731907 · record last updated 2026-10-16 · checked 2026-11-09 15:47 UTC